Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies
Conditions
Interventions
ACTR T Cell Product
Trastuzumab
Locations
6
United States
Yale Smilow Cancer Hospital
New Haven, Connecticut, United States
Miami University Cancer Center
Miami, Florida, United States
The Ohio State University
Columbus, Ohio, United States
Sarah Cannon Research Institute/Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Baylor Scott & White Medical Center
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
March 13, 2019
Primary Completion Date
March 12, 2020
Completion Date
March 12, 2020
Last Updated
March 31, 2020
NCT06898450
NCT05720117
NCT06658951
NCT05098132
NCT05223608
NCT05719558
Lead Sponsor
Cogent Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions